Table 2.

Results of therapy based on response (per-protocol population, n=25 ^a))

Variable	All patients (n=25)	Responders (n=3)	SD (n=17)	PD (n=5)	p-value
ECOG performance status					0.357
0	20 (80.0)	3 (100)	14 (82.4)	3 (60.0)
1	5 (20.0)	0	3 (17.6)	2 (40.0)
Tumor subtype					0.083
Skin	5 (20.0)	1 (33.3)	2 (11.8)	2 (40.0)
Acral	5 (20.0)	2 (66.7)	2 (11.8)	1 (20.0)
Mucosal	6 (24.0)	0	4 (23.5)	2 (40.0)
Choroidal	9 (36.0)	0	9 (52.9)	0
LDH level at baseline					0.599
Normal	13 (52.0)	1 (33.3)	10 (58.8)	2 (40.0)
Above normal	12 (48.0)	2 (66.7)	7 (41.2)	3 (60.0)
Liver metastasis	12 (48.0)	0	10 (58.8)	2 (40.0)	0.158
Lung metastasis	13 (52.0)	2 (66.7)	9 (52.9)	2 (40.0)	0.758
BRAF mutation					0.620
Wild type	21 (84.0)	2 (66.7)	15 (88.2)	4 (80.0)
V600E	4 (16.0)	1 (33.3)	2 (5.9)	1 (20.0)
c-Kit mutation					0.257
Wild type	13 (52.0)	2 (66.7)	8 (47.1)	3 (60.0)
Exon 11 mutation	1 (4.0)	0	0	1 (20.0)
Not evaluated	11 (44.0)	1 (33.3)	9 (52.9)	1 (20.0)
Previous chemotherapy regimen					0.461
Dacarbazine	22 (88.0)	2 (66.7)	15 (88.2)	5 (100)
Dacarbazine and vemurafenib	2 (8.0)	1 (33.3)	1 (5.9)	0
Cisplatin/vinblastine/dacarbazine	1 (4.0)	0	1 (5.9)	0
Previous radiotherapy	11 (44.0)	2 (66.7)	6 (35.3)	3 (60.0)	0.434
Median chemotherapy cycles (range)	5.5 (2-12)	8 (8-12)	6 (2-12)	2 (2)
Median progression-free survival (mo)	4.3	6.0	4.9	1.3	< 0.001
Median overall survival (mo)	9.6	9.6	9.9	5.9	0.194

Values are presented as number (%) unless otherwise indicated. SD, stable disease; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.

^a)Five patients were inevaluable.